Trevena (NASDAQ:TRVN) perks up 8% premarket in reaction to the announcement that its collaborator Imperial College London has initiated a proof-of-concept study for TRV027 in COVID-19 patients.
The trial will enroll ~60 hospitalized, non-ventilated patients aged 18 or older with a confirmed COVID-19 infection.
The primary objective is to evaluate whether TRV027 reduces abnormal clotting associated with COVID-19. The study will also assess the effect of TRV027 on lung function and other clinical outcomes.
Top-line data are expected in Q1 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.